Table 3 2SMR estimates of the causality between antidiabetic targets and AD
Target gene | Drugs | Action | Method | Numbers of SNPs | OR | 95% CI | P-value |
|---|---|---|---|---|---|---|---|
CPE | Insulin Human | Modulator (Unknown) | MR Egger | 3 | 0.98 | 0.82–1.17 | 0.86 |
Inverse variance weighted | 3 | 0.94 | 0.89–1.00 | 0.05 | |||
Weighted median | 3 | 0.95 | 0.89–1.01 | 0.08 | |||
Weighted mode | 3 | 0.95 | 0.89–1.01 | 0.24 | |||
ETFDH | Metformin | Inhibitor | Inverse variance weighted | 2 | 1.08 | 1.01–1.16 | 0.03 |
GANC | Miglitol | Antagonist | Inverse variance weighted | 2 | 1.09 | 1.02–1.18 | 0.02 |
MGAM | Voglibose | Inhibitor | Wald ratio | 1 | 1.04 | 1.00–1.09 | 0.04 |
Acarbose | Inhibitor | ||||||
Miglitol | Antagonist, inhibitor |